Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 12, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Gene expression profiling for early-stage NSCLC.

Frunze Petrosyan1, Hamed Daw, Abdo Haddad

  • 1Department of Internal Medicine, Fairview Hospital, Cleveland Clinic Hospital, Cleveland Clinic Health System, Cleveland, OH.

American Journal of Clinical Oncology
|April 24, 2013
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Treatment in Refractory Copper Deficiency: A Case Report.

Cureus·2026
Same author

Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Concern for 3-Ms Syndrome in a Patient With Metastatic Melanoma: A Case Report.

Cureus·2025
Same author

A Case of Secondary Hemophagocytic Lymphohistiocytosis in a Patient With T-cell Lymphoma.

Cureus·2024
Same author

Synergizing biotechnology and natural farming: pioneering agricultural sustainability through innovative interventions.

Frontiers in plant science·2024
Same author

Intramucosal Extent as a Marker for Advanced Disease and Survival in Gallbladder Adenocarcinoma.

The American surgeon·2024
Same author

Novel fluorobenzothiazole as a dual inhibitor of gyrase B and topoisomerase IV against Gram-positive pathogens.

Future microbiology·2023
Same journal

Care Patterns and Gastric Cancer-Related Outcomes in Patients With Pathogenic/Likely Pathogenic Germline CDH1 Variants: A 14-Year Single-Center Analysis.

American journal of clinical oncology·2026
Same journal

Upper Extremity Lymphedema​​​: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.

American journal of clinical oncology·2026
Same journal

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO).

American journal of clinical oncology·2026
Same journal

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same journal

Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.

American journal of clinical oncology·2026
Same journal

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026
See all related articles

Gene expression profiling shows promise as a biomarker for identifying stage I non-small cell lung carcinoma patients who may benefit from adjuvant treatment, improving personalized cancer care.

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Lung cancer remains a leading cause of cancer mortality globally, with high mortality rates even for early stages.
  • Current guidelines do not recommend adjuvant chemotherapy for stage I non-small cell lung carcinoma (NSCLC), necessitating prognostic markers.
  • Identifying patients who would benefit from adjuvant therapy is crucial for improving treatment outcomes.

Purpose of the Study:

  • To review major studies on gene expression profiling as a prognostic marker for stage I NSCLC.
  • To explore the potential of gene expression profiles for guiding adjuvant treatment decisions.
  • To discuss future prospects and lessons learned in the field of lung cancer biomarker discovery.

Main Methods:

  • Analysis of gene expression profiling from surgical specimens of resected lung cancers.

More Related Videos

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

Related Experiment Videos

Last Updated: May 12, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

  • Utilizing techniques such as microarray assays, RT-quantitative polymerase chain reaction, and microRNA-based methods.
  • Reviewing findings from numerous studies published over the last decade.

    • Main Results:

    • Gene expression profiling has demonstrated excellent predictive accuracy in multiple studies.
    • Various gene combinations, numbers, and identification methods have been reported.
    • Despite promising results, most profiles require further validation and prospective phase III studies.

    Conclusions:

    • Gene expression profiles hold significant potential as biomarkers for stage I NSCLC.
    • These profiles may soon be integrated into routine clinical practice for personalized treatment strategies.
    • Further validation and prospective studies are essential for widespread clinical implementation.